Headache News and Research

Latest Headache News and Research

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

New studies offer hope to women who want to get sexual mojo back

For women, passing midlife can deal a blow to their sex drive. But two new studies just published online in Menopause, the journal of The North American Menopause Society, offer hope to women who want to get their sexual mojo back.

5 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Researchers find that hay fever and allergies make migraines worse

People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.

26 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Obama tells insurers his 'fix' may cost them

President Barack Obama acknowledged to insurance executives that reinstating millions of insurance policies might cost them, according to Politico. Other media outlets report that brokers are worried about their role in the insurance marketplace and how one company is forecasting that a failure to enroll the uninsured could cut prescription drug sales by 30 percent in 2017.

20 Nov 2013

First Edition: November 19, 2013

Today's headlines include news that Obama administration officials were warned about the possibility of website difficulties months ago by an outside consulting firm.

19 Nov 2013

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions.

16 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

Women’s recovery from concussions may depend on menstrual cycle

How well a woman recovers from a concussion may depend on that time of the month.

14 Nov 2013

Viewpoints: Some who supported health law learning first-hand about the downsides; small businesses not finding better deals; Clinton should know there is no 'magic solution'

Margaret Davis of West L.A. voted for President Obama and appreciates the ideas behind the Affordable Care Act. She agrees that everyone should have access to healthcare and no one should be denied coverage because of pre-existing conditions. But here's the problem: She knows firsthand, as the new law of the land rolls clumsily into being, that it's not working out to everyone's advantage (Steve Lopez, 11/12).

14 Nov 2013

Flublok influenza vaccine for the 2013-14 season now available

Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.

14 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Headache News and Research

Latest Headache News and Research

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

College students not only bring dirty socks but also mononucleosis to home

EMA expands administration options for Hizentra

New studies offer hope to women who want to get sexual mojo back

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Researchers find that hay fever and allergies make migraines worse

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Obama tells insurers his 'fix' may cost them

First Edition: November 19, 2013

Intelliject to be recognized with George DiDomizio Industry Award

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Women’s recovery from concussions may depend on menstrual cycle

Viewpoints: Some who supported health law learning first-hand about the downsides; small businesses not finding better deals; Clinton should know there is no 'magic solution'

Flublok influenza vaccine for the 2013-14 season now available

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in